Structure-based Discovery of Narirutin as a Shikimate kinase Inhibitor with Anti-tubercular Potency

Author(s): Pramod Kumar Sahu, Pranab Kishor Mohapatra*, Dhanji Popatbhai Rajani, Mukesh Kumar Raval*

Journal Name: Current Computer-Aided Drug Design

Volume 16 , Issue 5 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Shikimate pathway is essential for tubercular bacillus but it is absent in mammals. Therefore, Shikimate kinase and other enzymes in the pathway are potential targets for the development of novel anti-tuberculosis drugs.

Objective: In the present study, Shikimate kinase is selected as the target for in silico screening of phytochemicals with an aim to discover a novel herbal drug against Mycobacterium tuberculosis (Mtb).

Methods: A structure-based drug discovery approach is undertaken for the execution of the objective. Virtual screening of phytochemical database NPACT against the target, Shikimate kinase (PDB ID 3BAF), is carried out followed by toxicity and drug-likeness filtration. Finally, a lead, narirutin was selected for in vitro anti-tubercular study.

Results: Narirutin, present in citrus fruits, emerges as the lead. It is considered to be non-toxic with predicted high LD50 value, 12000 mg/kg body weight. The phytochemical is tested for its antitubercular activity in vitro. It has MIC99 62.5 μg/mL against the MtbH37Rv strain.

Conclusion: This is the first-ever report to show anti-tuberculosis potency of narirutin.

Keywords: Molecular docking, Mycobacterium tuberculosis, narirutin, shikimate kinase, drug-likeness, toxicity.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 5
Year: 2020
Published on: 09 November, 2020
Page: [523 - 529]
Pages: 7
DOI: 10.2174/1573409915666191025112150
Price: $65

Article Metrics

PDF: 17